Yang Hang, Zhen Juan, Huang Xiaoyan, Chen Minqi, Cui Hongsi, Sheng Xia, Li Xinyu
Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin, China.
Department of Cadre Ward, The First Hospital of Jilin University, Changchun, Jilin, China.
Front Med (Lausanne). 2025 Jun 27;12:1544601. doi: 10.3389/fmed.2025.1544601. eCollection 2025.
Primary sclerosing cholangitis (PSC) represents a cholestatic disease hallmarked by persistent and progressive inflammation of the bile ducts. Despite its low incidence and unfavorable prognosis, there is no pharmacological therapy capable of altering the course of PSC, and liver transplantation is the only effective treatment. In the face of the landscape of PSC, pharmaceutical therapy encounters great challenges that demand expeditious resolution. However, at present, many drugs have been carried out to phase III clinical trials and are expected to be applied to the clinical treatment of PSC patients in the future. This review integrates relevant research findings from PubMed and Web of Science databases up to October 2024 over the past decade, excluding other liver diseases, such as fatty liver disease, viral hepatitis, and alcoholic liver disease. It covers the vast majority of drugs currently in clinical trials, and focus on the summary of hot research drugs, and summarizes the latest drug-based therapeutic for PSC. This review not only provides certain information for clinical research and treatment of PSC, but it is also the first time that stem cell therapy has been linked to PSC, which is expected to improve cholestasis and liver inflammation in patients with PSC. The article provides explanations and comparisons of different drugs, offering a basis for future researchers to choose medications.
原发性硬化性胆管炎（PSC）是一种以胆管持续进行性炎症为特征的胆汁淤积性疾病。尽管其发病率低且预后不佳，但目前尚无能够改变PSC病程的药物治疗方法，肝移植是唯一有效的治疗手段。面对PSC的现状，药物治疗面临着亟待解决的巨大挑战。然而，目前许多药物已进入III期临床试验，有望在未来应用于PSC患者的临床治疗。本综述整合了截至2024年10月过去十年间来自PubMed和Web of Science数据库的相关研究结果，排除了其他肝脏疾病，如脂肪肝、病毒性肝炎和酒精性肝病。它涵盖了目前绝大多数正在进行临床试验的药物，并重点总结了热门研究药物，概述了基于药物的PSC最新治疗方法。本综述不仅为PSC的临床研究和治疗提供了一定信息，而且首次将干细胞治疗与PSC联系起来，有望改善PSC患者的胆汁淤积和肝脏炎症。文章对不同药物进行了解释和比较，为未来研究人员选择药物提供了依据。
